In cholangiocarcinoma, FGFR2 fusions are generally mutually exclusive with alterations in MAPK pathway (KRAS, NRAS and BRAF) in baseline samples26, reflecting their roles as alternative oncogenic drivers. This evidence concerns the gene BRAF and cholangiocarcinoma.